The Integral Diagnostics Ltd (ASX: IDX) share price is in focus today after reporting preliminary FY26 results, with revenue climbing around 25% and operating NPAT surging by approximately 50%.
Image source: Getty Images
What did Integral Diagnostics report?
- Revenue expected at $788–$790 million, up ~25% from FY25 ($628.0m)
- Operating EBITDA forecast at $164–$165 million, up ~30% from FY25 ($126.5m)
- Operating EBITDA margin of ~20.8%–21.0%, 80 basis points higher vs last year
- Operating NPAT projected at $47–$48 million, up ~50% from FY25 ($31.6m)
- Diluted operating EPS estimated at 12.5c–12.7c, up ~23% from FY25 (10.2c)
- Net Debt to Operating EBITDA improved to 2.3x from 2.6x
What else do investors need to know?
Integral Diagnostics' preliminary numbers include a full twelve-month contribution from the Capitol Health acquisition, which previously had only a partial year impact. Capital expenditure was $50 million, falling within the company's guidance range.
In leadership news, Integral Diagnostics has appointed Ms Jenny Martin as its new Chief Financial Officer. She brings over 25 years' experience in finance and healthcare technology, taking over from outgoing CFO Craig White, who will retire following an orderly transition period.
What's next for Integral Diagnostics?
Shareholders can expect audited FY26 results as scheduled on 25 August 2026, with a results roadshow planned featuring both the new and outgoing CFO. The leadership transition, coupled with improved balance sheet discipline and continued investment, positions IDX for its next stage of growth across Australia and New Zealand.
Integral Diagnostics' outlook includes a focus on operational discipline, integrating recent acquisitions, and enhancing its unique medical leadership model to support future expansion.
Integral Diagnostics share price snapshot
Over the past 12 months, Integral Diagnostics shares have declined 20%, trailing the All Ordinaries Index (ASX: XAO), which has risen 5% over the same period.
